Health · Medical Research · 1 hr ago
First participant completes 36-week phase of Neurizon ALS trial
Neurizon Therapeutics’ first trial participant completed the 36-week randomised phase of its study of NUZ-001, an experimental treatment for ALS.
The trial is part of a Phase 2/3 study run across 78 US clinical sites, with 250 participants enrolled.
ALS is the most common form of motor neurone disease, which affects nerve cells that control movement.
The participant moved into an optional extension where everyone receives NUZ-001, regardless of their original treatment assignment.
The extension will add longer-term safety and health data, but it is not a separate controlled test of whether the treatment works.
The main trial results are expected in late Q2 2027 and could support a regulatory submission if they meet applicable requirements.
Neurizon also drew down about $3.7 million from a financing facility, secured against its estimated FY27 R&D tax rebate, to help fund its trial commitments.
The first participant in Regimen I of Neurizon Therapeutics’ Phase 2/3 ALS Platform Trial completed the 36-week randomised phase and entered an optional treatment extension.
The trial enrolled 250 participants across 78 US clinical sites.
Participants in the extension receive investigational NUZ-001, regardless of their original treatment allocation.
Topline results from the randomised phase are expected in late Q2 CY27.
Neurizon also completed a second drawdown of about $3.7 million under its R&D financing facility with Dare Capital Loan Fund.
- Who
- The first participant in Regimen I of Neurizon Therapeutics’ Phase 2/3 ALS Platform Trial.
- What
- The participant completed the 36-week randomised phase and entered the Active Treatment Extension.
- When
- The completion date is not stated.
- Where
- The trial is being conducted across 78 US clinical sites.
- Why
- The extension is designed to collect longer-term safety, tolerability, functional and biomarker data.
This story does not have two clearly opposing sides.
Neurizon completed enrolment of all 250 participants in Regimen I.
The first participant completed the randomised phase and transitioned into the Active Treatment Extension.
- Trial participants
- 250
- Activated clinical sites
- 78 US sites
- Randomised phase
- 36 weeks
- Expected topline results
- Late Q2 CY27
- Second R&D financing drawdown
- About $3.7 million
What people are saying
The extension provides an opportunity to build our understanding of NUZ-001 through longer-term treatment